News

A Daughter’s Story of Advocacy After Loss Jennifer L. fondly remembers the long road trips she took as a child with her mom, Jacqueline. With a car stocked full of CDs and the open road ahead of them, they’d belt out lyrics, make spontaneous pit stops, and have uninterrupted conversations that stretched for miles. “Road trips were our one-on-one time without any […] June 20, 2025

When Life Doesn’t Pause: A Young Adult’s Story of Family, Work, and Brain Cancer Melissa M. sat in the OR waiting room, one hand resting on her belly, the other gripping a hospital chair. At nine months pregnant, she was about to give birth to their daughter — but first, her husband, Joe, had to make it through a craniotomy following a brain tumor recurrence. “It was so hard,” […] April 1, 2025

New Brain Tumor Clinical Trials: April – October 2024 It can be hard to keep track of new clinical trial opportunities opening across the United States. There are many clinical trials actively enrolling patients. This report provides a summary of the studies that have recently opened or started recruiting since our last report for patients with a primary brain tumor. Follow the hyperlink for […] November 7, 2024

Updated: Exciting News for Patients with Grade 2 Oligodendroglioma and Astrocytoma UPDATED (August 6, 2024): The U.S. Food and Drug Administration (FDA) has approved vorasidenib (brand name: Voranigo) for the treatment of adult and pediatric patients 12 years of age and older with grade 2 astrocytoma or oligodendroglioma with an IDH1 or IDH2 mutation, following surgery including biopsy, sub-total resection, or gross total resection. This is […] August 6, 2024

New Brain Tumor Clinical Trials: January – March 2024 It can be hard to keep track of new clinical trial opportunities opening across the United States. There are many clinical trials actively enrolling patients. This report provides a summary of the studies that have recently opened or started recruiting (January 1, 2024 – April 9, 2024) for patients with a primary brain tumor*. Follow […] April 12, 2024